{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:23:02Z","timestamp":1785784982784,"version":"3.56.0"},"reference-count":207,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004621","name":"Kerman University of Medical Sciences","doi-asserted-by":"publisher","award":["402000015"],"award-info":[{"award-number":["402000015"]}],"id":[{"id":"10.13039\/501100004621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.cca.2024.117824","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T11:10:43Z","timestamp":1706958643000},"page":"117824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Prostate cancer: Novel genetic and immunologic biomarkers"],"prefix":"10.1016","volume":"555","author":[{"given":"Mohammad","family":"Samare-Najaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosein","family":"Kouchaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed","family":"Moein Mahini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Saberi Rounkian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasaman","family":"Tavakoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Samareh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Karim Azadbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Jamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2024.117824_b0005","doi-asserted-by":"crossref","unstructured":"H. Sung, et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Can. J. Clin. 71(3) (2021) 209\u2013249.","DOI":"10.3322\/caac.21660"},{"issue":"4","key":"10.1016\/j.cca.2024.117824_b0010","first-page":"332","article-title":"Darolutamide as a second-generation androgen receptor inhibitor in the treatment of prostate cancer","volume":"21","author":"Abbasi","year":"2021","journal-title":"Curr. Mol. Med."},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0015","article-title":"Global cancer statistics 2022: the trends projection analysis","volume":"10","author":"Chhikara","year":"2023","journal-title":"Chemical Biology Letters"},{"key":"10.1016\/j.cca.2024.117824_b0020","doi-asserted-by":"crossref","unstructured":"Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2018. CA: a cancer journal for clinicians, 2018. 68(1): p. 7-30.","DOI":"10.3322\/caac.21442"},{"issue":"20","key":"10.1016\/j.cca.2024.117824_b0025","first-page":"2019","article-title":"Global cancer observatory: cancer today","volume":"3","author":"Ferlay","year":"2018","journal-title":"Lyon, France: International Agency for Research on Cancer"},{"key":"10.1016\/j.cca.2024.117824_b0030","doi-asserted-by":"crossref","unstructured":"C.E. DeSantis, et al., Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA: A Can. J. Clin. 66(4) (2016) 290-308.","DOI":"10.3322\/caac.21340"},{"issue":"6","key":"10.1016\/j.cca.2024.117824_b0035","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.eururo.2018.02.016","article-title":"Twenty-year risk of prostate cancer death by midlife prostate-specific antigen and a panel of four kallikrein markers in a large population-based cohort of healthy men","volume":"73","author":"Sjoberg","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.cca.2024.117824_b0040","article-title":"Non-invasive diagnosis of endometriosis: immunologic and genetic markers","author":"Mahini","year":"2022","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0045","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2174\/1573394718666220930143651","article-title":"The Effect of Metformin on Bad, Bak, and Bim Pro-apoptotic Factors: A Molecular Dynamic Simulation Study","volume":"19","author":"Jamali","year":"2023","journal-title":"Current Cancer Therapy Reviews"},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.eururo.2009.08.025","article-title":"A risk-based strategy improves prostate-specific antigen\u2013driven detection of prostate cancer","volume":"57","author":"Roobol","year":"2010","journal-title":"Eur. Urol."},{"issue":"127","key":"10.1016\/j.cca.2024.117824_b0055","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003180","article-title":"Beyond PSA: the next generation of prostate cancer biomarkers","volume":"4","author":"Prensner","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"21","key":"10.1016\/j.cca.2024.117824_b0060","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMcp1103642","article-title":"Screening for prostate cancer","volume":"365","author":"Hoffman","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.cca.2024.117824_b0065","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41379-020-0551-y","article-title":"Novel artificial intelligence system increases the detection of prostate cancer in whole slide images of core needle biopsies","volume":"33","author":"Raciti","year":"2020","journal-title":"Mod. Pathol."},{"issue":"6","key":"10.1016\/j.cca.2024.117824_b0070","first-page":"623","article-title":"Risk factors associated with transrectal ultrasound guided prostate needle biopsy in patients with prostate cancer","volume":"32","author":"Lee","year":"2009","journal-title":"Chang Gung Med. J."},{"issue":"9","key":"10.1016\/j.cca.2024.117824_b0075","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.3390\/ijms22094367","article-title":"Biomarkers in prostate cancer diagnosis: From current knowledge to the role of metabolomics and exosomes","volume":"22","author":"Salciccia","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.cca.2024.117824_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-028576","article-title":"What is an invasive procedure? A definition to inform study design, evidence synthesis and research tracking","volume":"9","author":"Cousins","year":"2019","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.cca.2024.117824_b0085","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ajur.2018.11.007","article-title":"Diagnosis of prostate cancer","volume":"6","author":"Descotes","year":"2019","journal-title":"Asian Journal of Urology"},{"issue":"10","key":"10.1016\/j.cca.2024.117824_b0090","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.3390\/cancers12102988","article-title":"Validating fPSA glycoprofile as a prostate cancer biomarker to avoid unnecessary biopsies and re-biopsies","volume":"12","author":"Bertok","year":"2020","journal-title":"Cancers"},{"issue":"20","key":"10.1016\/j.cca.2024.117824_b0095","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/hmg\/10.20.2313","article-title":"Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease","volume":"10","author":"Nwosu","year":"2001","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.cca.2024.117824_b0100","first-page":"79","article-title":"Prostate cancer genetics: a review","volume":"26","author":"Wallis","year":"2015","journal-title":"Ejifcc"},{"issue":"2","key":"10.1016\/j.cca.2024.117824_b0105","first-page":"51","article-title":"Biomarkers for prostate cancer diagnosis from genetic perspectives","volume":"2","author":"Khatami","year":"2020","journal-title":"Translat. Res. Urol."},{"issue":"8","key":"10.1016\/j.cca.2024.117824_b0110","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.biocel.2009.12.014","article-title":"MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for therapy","volume":"42","author":"Cho","year":"2010","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.cca.2024.117824_b0115","first-page":"1","article-title":"Omics-based novel strategies in the diagnosis of endometriosis","author":"Samare-Najaf","year":"2023","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.12954\/PI.12011","article-title":"MicroRNAs in prostate cancer","volume":"1","author":"Kim","year":"2013","journal-title":"Prostate Int."},{"issue":"2","key":"10.1016\/j.cca.2024.117824_b0125","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/onc.2013.54","article-title":"Roles of microRNAs during prostatic tumorigenesis and tumor progression","volume":"33","author":"Fang","year":"2014","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.cca.2024.117824_b0130","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/cr.2008.282","article-title":"Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases","volume":"18","author":"Chen","year":"2008","journal-title":"Cell Res."},{"issue":"2","key":"10.1016\/j.cca.2024.117824_b0135","article-title":"MicroRNAs as diagnostic, prognostic, and therapeutic biomarkers in prostate cancer. Critical Reviews\u2122 in Eukaryotic","volume":"29","author":"Aghdam","year":"2019","journal-title":"Gene Expr."},{"issue":"06","key":"10.1016\/j.cca.2024.117824_b0140","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2217\/epi-2019-0275","article-title":"miRNA in prostate cancer: challenges toward translation","volume":"12","author":"Abramovic","year":"2020","journal-title":"Epigenomics"},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-50172-6","article-title":"Semen miRNAs contained in exosomes as non-invasive biomarkers for prostate cancer diagnosis","volume":"9","author":"Barcel\u00f3","year":"2019","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.cca.2024.117824_b0150","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.eururo.2015.12.054","article-title":"The potential of microRNAs as prostate cancer biomarkers","volume":"70","author":"Fabris","year":"2016","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0155","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20211972","article-title":"Prognostic value of miR-21 for prostate cancer: a systematic review and meta-analysis","volume":"42","author":"Stafford","year":"2022","journal-title":"Biosci. Rep."},{"issue":"9","key":"10.1016\/j.cca.2024.117824_b0160","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s11255-018-1938-2","article-title":"Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition","volume":"50","author":"Porzycki","year":"2018","journal-title":"Int. Urol. Nephrol."},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0165","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41525-021-00212-w","article-title":"Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer","volume":"6","author":"Shin","year":"2021","journal-title":"NPJ Genom. Med."},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0170","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5152\/tud.2019.19163","article-title":"Urine miR-21-5p and miR-200c-3p as potential non-invasive biomarkers in patients with prostate cancer","volume":"46","author":"Danarto","year":"2020","journal-title":"Turk. J. Urol."},{"issue":"6","key":"10.1016\/j.cca.2024.117824_b0175","doi-asserted-by":"crossref","DOI":"10.5812\/ijcm.110014","article-title":"Non-invasive Prostate Cancer Detection by Measuring Expression Level of miR-21 and miR-214 in Urine","volume":"14","author":"Emamvirdizadeh","year":"2015","journal-title":"International Journal of Cancer Management"},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0180","first-page":"618","article-title":"miR-17-3P regulates the proliferation and survival of colon cancer cells by targeting Par4","volume":"17","author":"Lu","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"10","key":"10.1016\/j.cca.2024.117824_b0185","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1158\/1078-0432.CCR-18-2849","article-title":"Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate CancerSerum miRNA Biomarker for Prostate Cancer","volume":"25","author":"Urabe","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.cca.2024.117824_b0190","first-page":"6943","article-title":"Combinations of elevated tissue miRNA-17-92 cluster expression and serum prostate-specific antigen as potential diagnostic biomarkers for prostate cancer","volume":"14","author":"Feng","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.cca.2024.117824_b0195","doi-asserted-by":"crossref","first-page":"11069","DOI":"10.2147\/OTT.S230963","article-title":"miR-451: A Novel Biomarker and Potential Therapeutic Target for Cancer","volume":"12","author":"Bai","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"17","key":"10.1016\/j.cca.2024.117824_b0200","doi-asserted-by":"crossref","first-page":"13894","DOI":"10.18632\/oncotarget.24532","article-title":"Exosomal microRNA profiling to identify hypoxia-related biomarkers in prostate cancer","volume":"9","author":"Panigrahi","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.cca.2024.117824_b0205","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000495473","article-title":"Decreased miR-218\u20135p levels as a serum biomarker in bone metastasis of prostate cancer","volume":"42","author":"Peng","year":"2019","journal-title":"Oncology Research and Treatment"},{"issue":"9","key":"10.1016\/j.cca.2024.117824_b0215","doi-asserted-by":"crossref","first-page":"e23137","DOI":"10.1002\/jbt.23137","article-title":"Identification of novel biomarkers in prostate cancer diagnosis and prognosis","volume":"36","author":"Li","year":"2022","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0220","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/21691401.2018.1553783","article-title":"MiR-30a-5p frequently downregulated in prostate cancer inhibits cell proliferation via targeting PCLAF","volume":"47","author":"Zhao","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"13","key":"10.1016\/j.cca.2024.117824_b0225","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/pros.22495","article-title":"A panel of five circulating microRNAs as potential biomarkers for prostate cancer","volume":"72","author":"Chen","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.cca.2024.117824_b0230","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fmolb.2023.980433","article-title":"Plasma and urinary extracellular vesicles as a source of RNA biomarkers for prostate cancer in liquid biopsies","volume":"10","author":"Bajo-Santos","year":"2023","journal-title":"Front. Mol. Biosci."},{"issue":"4","key":"10.1016\/j.cca.2024.117824_b0235","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.21037\/tau-20-421","article-title":"MiR-30b-3p and miR-126-3p of urinary extracellular vesicles could be new biomarkers for prostate cancer","volume":"10","author":"Matsuzaki","year":"2021","journal-title":"Translat. Androl. Urol."},{"issue":"4","key":"10.1016\/j.cca.2024.117824_b0240","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.gendis.2021.02.002","article-title":"miR-106b as an emerging therapeutic target in cancer","volume":"9","author":"Sagar","year":"2022","journal-title":"Genes Diseases"},{"key":"10.1016\/j.cca.2024.117824_b0245","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s11684-014-0353-z","article-title":"Effects of miR-200c on the migration and invasion abilities of human prostate cancer Du145 cells and the corresponding mechanism","volume":"8","author":"Shi","year":"2014","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0250","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13046-023-02685-2","article-title":"miR-92a-1-5p enriched prostate cancer extracellular vesicles regulate osteoclast function via MAPK1 and FoxO1","volume":"42","author":"Yu","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0255","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yexmp.2013.12.004","article-title":"miR-126 in human cancers: clinical roles and current perspectives","volume":"96","author":"Ebrahimi","year":"2014","journal-title":"Exp. Mol. Pathol."},{"issue":"6","key":"10.1016\/j.cca.2024.117824_b0260","first-page":"9051","article-title":"MicroRNA-126 inhibits proliferation and metastasis in prostate cancer via regulation of ADAM9","volume":"15","author":"Hua","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.cca.2024.117824_b0265","first-page":"1","article-title":"Development and validation of a urinary microRNA Biomarker panel as a tool for early detection of prostate cancer in a chinese population","volume":"just-accepted","author":"Zhan","year":"2023","journal-title":"Biomarkers"},{"issue":"23","key":"10.1016\/j.cca.2024.117824_b0270","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.3390\/cells11233776","article-title":"LncRNA\/miRNA\/mRNA network introduces novel biomarkers in prostate cancer","volume":"11","author":"Taheri","year":"2022","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.cca.2024.117824_b0275","doi-asserted-by":"crossref","first-page":"924","DOI":"10.4161\/rna.24604","article-title":"On the classification of long non-coding RNAs","volume":"10","author":"Ma","year":"2013","journal-title":"RNA Biol."},{"key":"10.1016\/j.cca.2024.117824_b0280","first-page":"1","article-title":"The constructive and destructive impact of autophagy on both genders\u2019 reproducibility, a comprehensive review","author":"Samare-Najaf","year":"2023","journal-title":"Autophagy"},{"issue":"6","key":"10.1016\/j.cca.2024.117824_b0285","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.molcel.2009.01.026","article-title":"An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles","volume":"33","author":"Clemson","year":"2009","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.cca.2024.117824_b0290","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jmoldx.2014.06.009","article-title":"Long noncoding RNAs as putative biomarkers for prostate cancer detection","volume":"16","author":"Lee","year":"2014","journal-title":"J. Mol. Diagn."},{"issue":"61","key":"10.1016\/j.cca.2024.117824_b0295","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.18632\/oncotarget.27284","article-title":"The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer","volume":"10","author":"Lemos","year":"2019","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.cca.2024.117824_b0300","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.juro.2012.04.143","article-title":"Toward the detection of prostate cancer in urine: a critical analysis","volume":"189","author":"Truong","year":"2013","journal-title":"J. Urol."},{"issue":"5","key":"10.1016\/j.cca.2024.117824_b0305","first-page":"E214","article-title":"Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: A systematic review and meta-analysis","volume":"14","author":"Rodr\u00edguez","year":"2020","journal-title":"Can. Urol. Assoc. J."},{"issue":"12","key":"10.1016\/j.cca.2024.117824_b0310","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.3390\/cancers12123790","article-title":"Commercialized blood-, urinary-and tissue-based biomarker tests for prostate cancer diagnosis and prognosis","volume":"12","author":"Visser","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2024.117824_b0315","doi-asserted-by":"crossref","unstructured":"M. Dall\u2019Era, Liquid biomarkers in active surveillance. World J. Urol. 2021: p. 1-6.","DOI":"10.1007\/s00345-021-03609-5"},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0320","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/JU.0000000000001691","article-title":"Specific detection of prostate cancer cells in urine by RNA in situ hybridization","volume":"206","author":"Eskra","year":"2021","journal-title":"J. Urol."},{"key":"10.1016\/j.cca.2024.117824_b0325","first-page":"149","article-title":"PCA3 and TMPRSS2: ERG urine level as diagnostic biomarker of prostate cancer","author":"Warli","year":"2023","journal-title":"Res. Rep. Urol."},{"issue":"16","key":"10.1016\/j.cca.2024.117824_b0330","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.3390\/cancers13164075","article-title":"A novel urine exosomal lncRNA assay to improve the detection of prostate cancer at initial biopsy: a retrospective multicenter diagnostic feasibility study","volume":"13","author":"Li","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2024.117824_b0335","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.736110","article-title":"Effective diagnosis of prostate cancer based on mRNAs from urinary exosomes","volume":"9","author":"Gan","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.cca.2024.117824_b0340","first-page":"46","article-title":"PCA3 and TMPRSS2: ERG genes expression in biopsies of benign prostate hyperplasia, intraepithelial neoplasia, and prostate cancer","volume":"5","author":"Mikhaylenko","year":"2015","journal-title":"Urologiia"},{"issue":"9","key":"10.1016\/j.cca.2024.117824_b0345","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/iju.13734","article-title":"Urinary biomarkers of prostate cancer","volume":"25","author":"Fujita","year":"2018","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.cca.2024.117824_b0350","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1686991","article-title":"Urinary PCA3 a superior diagnostic biomarker for prostate cancer among ghanaian men","volume":"2022","author":"Opoku Mensah","year":"2022","journal-title":"Dis. Markers"},{"issue":"36","key":"10.1016\/j.cca.2024.117824_b0355","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2013.52.8505","article-title":"Can urinary PCA3 supplement PSA in the early detection of prostate cancer?","volume":"32","author":"Wei","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cca.2024.117824_b0360","unstructured":"U.F.a.D. Administration, Summary of Safety and Effectiveness Data: PROGENSA PCA3 Assay, 2012. 2012; Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf10\/P100033b.pdf."},{"issue":"5","key":"10.1016\/j.cca.2024.117824_b0365","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.eururo.2010.06.038","article-title":"External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome","volume":"58","author":"Auprich","year":"2010","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.cca.2024.117824_b0370","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.juro.2011.10.133","article-title":"Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2: ERG gene fusion","volume":"187","author":"Salagierski","year":"2012","journal-title":"J. Urol."},{"key":"10.1016\/j.cca.2024.117824_b0375","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3964615","article-title":"Detection of prostate cancer antigen 3 and prostate cancer susceptibility candidate in non-DRE urine improves diagnosis of prostate cancer in chinese population","volume":"2020","author":"Ye","year":"2020","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.cca.2024.117824_b0380","first-page":"1","article-title":"Long noncoding RNAs CAT2064 and CAT2042 may function as diagnostic biomarkers for prostate cancer by affecting target MicrorRNAs","author":"Amirmahani","year":"2021","journal-title":"Indian J. Clin. Biochem."},{"issue":"11","key":"10.1016\/j.cca.2024.117824_b0385","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/pros.23538","article-title":"Two long non-coding RNAs, Prcat17. 3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer","volume":"78","author":"Bayat","year":"2018","journal-title":"Prostate"},{"issue":"8","key":"10.1016\/j.cca.2024.117824_b0390","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.neo.2016.07.001","article-title":"Identification and validation of PCAT14 as prognostic biomarker in prostate cancer","volume":"18","author":"Shukla","year":"2016","journal-title":"Neoplasia"},{"key":"10.1016\/j.cca.2024.117824_b0395","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9494619","article-title":"lncRNA PCAT14 is a diagnostic marker for prostate cancer and is associated with immune cell infiltration","volume":"2021","author":"Yan","year":"2021","journal-title":"Dis. Markers"},{"key":"10.1016\/j.cca.2024.117824_b0400","article-title":"Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0405","doi-asserted-by":"crossref","first-page":"7349","DOI":"10.1038\/s41467-021-26901-9","article-title":"The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer","volume":"12","author":"Singh","year":"2021","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.cca.2024.117824_b0410","first-page":"588","article-title":"[Long noncoding RNA Linc00662 promotes the tumorigenesis of prostate cancer cells]. Zhonghua nan ke xue =","volume":"26","author":"Yao","year":"2020","journal-title":"Natl. J. Androl."},{"key":"10.1016\/j.cca.2024.117824_b0415","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cca.2015.02.018","article-title":"Using circular RNA as a novel type of biomarker in the screening of gastric cancer","volume":"444","author":"Li","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"4","key":"10.1016\/j.cca.2024.117824_b0420","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cell.2019.01.025","article-title":"Widespread and functional RNA circularization in localized prostate cancer","volume":"176","author":"Chen","year":"2019","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.cca.2024.117824_b0425","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.molcel.2015.03.027","article-title":"Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed","volume":"58","author":"Rybak-Wolf","year":"2015","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.cca.2024.117824_b0430","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1177\/1535370217708978","article-title":"Circular RNA\u2013new member of noncoding RNA with novel functions","volume":"242","author":"Hsiao","year":"2017","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.cca.2024.117824_b0435","first-page":"12","article-title":"Prognostic and diagnostic value of circRNA expression in prostate cancer: a systematic review and meta-analysis","author":"Xie","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2024.117824_b0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-021-01388-6","article-title":"A urine extracellular vesicle circRNA classifier for detection of high-grade prostate cancer in patients with prostate-specific antigen 2\u201310 ng\/mL at initial biopsy","volume":"20","author":"He","year":"2021","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.cca.2024.117824_b0445","first-page":"1045","article-title":"Differential expression profiles of circRNAs in human prostate cancer based on chip and bioinformatic analysis","volume":"13","author":"Ge","year":"2020","journal-title":"Int. J. Clin. Exp. Path."},{"issue":"5","key":"10.1016\/j.cca.2024.117824_b0450","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1159\/000494870","article-title":"Circular RNA expression profiling identifies prostate cancer-specific circRNAs in prostate cancer","volume":"50","author":"Xia","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0455","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/cancers14010202","article-title":"The emerging role of piwi-interacting rnas (Pirnas) in gastrointestinal cancers: an updated perspective","volume":"14","author":"Riquelme","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2024.117824_b0460","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.695077","article-title":"Piwi-interacting RNAs: A new class of regulator in human breast cancer","volume":"11","author":"Qian","year":"2021","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.cca.2024.117824_b0465","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3390\/diagnostics11101828","article-title":"Identification of PiRNA targets in urinary extracellular vesicles for the diagnosis of prostate cancer","volume":"11","author":"Peng","year":"2021","journal-title":"Diagnostics"},{"issue":"5","key":"10.1016\/j.cca.2024.117824_b0470","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccr.2014.03.017","article-title":"Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy","volume":"25","author":"Aytes","year":"2014","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.cca.2024.117824_b0475","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3892\/ijo.2013.2117","article-title":"Aberrant expression of the PRAC gene in prostate cancer","volume":"43","author":"Lenka","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.cca.2024.117824_b0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2021.01.106","article-title":"TPX2 mediates prostate cancer epithelial-mesenchymal transition through CDK1 regulated phosphorylation of ERK\/GSK3\u03b2\/SNAIL pathway","volume":"546","author":"Zhang","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0485","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12894-022-00969-x","article-title":"PCGEM1 promotes proliferation, migration and invasion in prostate cancer by sponging miR-506 to upregulate TRIAP1","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Urol."},{"issue":"2","key":"10.1016\/j.cca.2024.117824_b0490","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/JU.0000000000001374","article-title":"A urine exosome gene expression panel distinguishes between indolent and aggressive prostate cancers at biopsy","volume":"205","author":"Kohaar","year":"2021","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0495","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/ERC-21-0085","article-title":"Inhibition of GATA2 in prostate cancer by a clinically available small molecule","volume":"29","author":"Kaochar","year":"2022","journal-title":"Endocr. Relat. Cancer"},{"issue":"4","key":"10.1016\/j.cca.2024.117824_b0500","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/JU.0000000000001066","article-title":"Urine extracellular vesicle GATA2 mRNA discriminates biopsy result in men with suspicion of prostate cancer","volume":"204","author":"Woo","year":"2020","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0505","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1038\/s41598-018-22594-1","article-title":"PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis","volume":"8","author":"Bravaccini","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0510","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1038\/s41467-021-25623-2","article-title":"Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression","volume":"12","author":"Goel","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cca.2024.117824_b0515","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2147\/OTT.S221276","article-title":"Plasma messenger RNAs identified through bioinformatics analysis are novel, non-invasive prostate cancer biomarkers","volume":"13","author":"Wang","year":"2020","journal-title":"OncoTargets and Therapy"},{"issue":"16","key":"10.1016\/j.cca.2024.117824_b0520","doi-asserted-by":"crossref","first-page":"12797","DOI":"10.3390\/ijms241612797","article-title":"Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers","volume":"24","author":"Rafikova","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2024.117824_b0525","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3389\/fonc.2020.00846","article-title":"LPAR1, correlated with immune infiltrates, is a potential prognostic biomarker in prostate cancer","volume":"10","author":"Shi","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2024.117824_b0530","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.517637","article-title":"The landscape of immune cells infiltrating in prostate cancer","volume":"10","author":"Wu","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2024.117824_b0535","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2021.10.027","article-title":"The evolving role of immune cells in prostate cancer","volume":"525","author":"Wang","year":"2022","journal-title":"Cancer Lett."},{"issue":"15","key":"10.1016\/j.cca.2024.117824_b0540","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1002\/cam4.4060","article-title":"Interleukin-25: New perspective and state-of-the-art in cancer prognosis and treatment approaches","volume":"10","author":"Gowhari Shabgah","year":"2021","journal-title":"Cancer Med."},{"issue":"10","key":"10.1016\/j.cca.2024.117824_b0545","doi-asserted-by":"crossref","first-page":"845","DOI":"10.5306\/wjco.v12.i10.845","article-title":"Relationship between Th17 immune response and cancer","volume":"12","author":"Marques","year":"2021","journal-title":"World Journal of Clinical Oncology"},{"key":"10.1016\/j.cca.2024.117824_b0550","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4910595","article-title":"Expression levels of IL-17A, IL-17F, IL-17RA, and IL-17RC in prostate cancer with taking into account the histological grade according to Gleason scale in comparison to benign prostatic hyperplasia: in search of new therapeutic options","author":"Janiczek","year":"2020","journal-title":"J. Immunol. Res."},{"issue":"10","key":"10.1016\/j.cca.2024.117824_b0555","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/pros.23990","article-title":"CD4+ T helper 17 cell response of aged mice promotes prostate cancer cell migration and invasion","volume":"80","author":"Liu","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.cca.2024.117824_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119132","article-title":"The role of regulatory T cells in the pathogenesis and treatment of prostate cancer","volume":"284","author":"Karpisheh","year":"2021","journal-title":"Life Sci."},{"issue":"15","key":"10.1016\/j.cca.2024.117824_b0565","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/pros.24213","article-title":"Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment","volume":"81","author":"Sun","year":"2021","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0570","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bju.14893","article-title":"Prostate cancer cells enhance interleukin-15-mediated expansion of NK cells","volume":"125","author":"Sakellariou","year":"2020","journal-title":"BJU Int."},{"issue":"9","key":"10.1016\/j.cca.2024.117824_b0575","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1113\/EP088627","article-title":"Natural killer cell mobilization and egress following acute exercise in men with prostate cancer","volume":"105","author":"Hanson","year":"2020","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.cca.2024.117824_b0580","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.3389\/fimmu.2020.586126","article-title":"Prostate cancer peripheral blood NK cells show enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 production and secrete monocyte-recruiting and polarizing factors","volume":"11","author":"Gallazzi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2024.117824_b0585","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1590\/s1677-5538.ibju.2019.0268","article-title":"Can natural killer cell activity help screen patients requiring a biopsy for the diagnosis of prostate cancer?","volume":"46","author":"Tae","year":"2020","journal-title":"Int. Braz J Urol"},{"issue":"15","key":"10.1016\/j.cca.2024.117824_b0590","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.3390\/ijms21155484","article-title":"Current status and future perspectives of checkpoint inhibitor immunotherapy for prostate cancer: a comprehensive review","volume":"21","author":"Kim","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.cca.2024.117824_b0595","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1515\/reveh-2020-0051","article-title":"Mechanistic targets for BPH and prostate cancer\u2013a review","volume":"36","author":"Shah","year":"2021","journal-title":"Rev. Environ. Health"},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0600","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-020-02370-4","article-title":"Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer","volume":"18","author":"Ryan","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cca.2024.117824_b0605","article-title":"Serum multi-cytokines screening identifies TRAIL and IL-10 as probable new biomarkers for prostate health index diagnostic utility adjustment in grey zone aggressive prostate cancer detection: A single-center data in China","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2024.117824_b0610","doi-asserted-by":"crossref","unstructured":"Z. Culig, Interleukin-6 function and targeting in prostate cancer. Tumor Microenvironment: The Role of Interleukins\u2013Part B, 2021: p. 1-8.","DOI":"10.1007\/978-3-030-55617-4_1"},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0615","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s40001-022-00807-8","article-title":"Selective biomarkers for inflammation and infection are associated with post-operative complications following transperineal template prostate biopsy (TTPB): a single-centre observational clinical pilot-study","volume":"27","author":"Snyper","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.cca.2024.117824_b0620","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fsens.2022.789771","article-title":"Sensing soluble immune checkpoint molecules and disease-relevant cytokines in cancer: a novel paradigm in disease diagnosis and monitoring","volume":"3","author":"Pandey","year":"2022","journal-title":"Front. Sens."},{"issue":"3","key":"10.1016\/j.cca.2024.117824_b0625","doi-asserted-by":"crossref","first-page":"e0247055","DOI":"10.1371\/journal.pone.0247055","article-title":"Statistical meta-analysis to investigate the association between the Interleukin-6 (IL-6) gene polymorphisms and cancer risk","volume":"16","author":"Harun-Or-Roshid","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0630","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s12967-022-03731-x","article-title":"Differential regulation of TNF\u03b1 and IL-6 expression contributes to immune evasion in prostate cancer","volume":"20","author":"Deichaite","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cca.2024.117824_b0635","doi-asserted-by":"crossref","first-page":"8542376","DOI":"10.1155\/2022\/8542376","article-title":"Exploration of the Value of Combined UA, IL-6, and fPSA\/tPSA in the Diagnosis of Prostate Cancer","volume":"2022","author":"Tang","year":"2022","journal-title":"Comput. Math. Methods Med."},{"issue":"5","key":"10.1016\/j.cca.2024.117824_b0640","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/pros.24299","article-title":"Plasma IL-6 and TNF-\u03b1 levels correlate significantly with grading changes in localized prostate cancer","volume":"82","author":"Zhou","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.cca.2024.117824_b0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2020.120909","article-title":"Highly sensitive impedimetric immunosensor for determination of interleukin 6 as a cancer biomarker by using conjugated polymer containing epoxy side groups modified disposable ITO electrode","volume":"215","author":"Ayd\u0131n","year":"2020","journal-title":"Talanta"},{"issue":"7","key":"10.1016\/j.cca.2024.117824_b0650","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jfma.2019.10.016","article-title":"Association between interleukin-8 rs4073 polymorphism and prostate cancer: a meta-analysis","volume":"119","author":"Chen","year":"2020","journal-title":"J. Formos. Med. Assoc."},{"issue":"6","key":"10.1016\/j.cca.2024.117824_b0655","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2217\/fon-2021-0683","article-title":"IL-6 and IL-8 cytokines are associated with elevated prostate-specific antigen levels among patients with adenocarcinoma of the prostate at the Uganda Cancer Institute","volume":"18","author":"Katongole","year":"2022","journal-title":"Future Oncol."},{"issue":"16","key":"10.1016\/j.cca.2024.117824_b0660","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/pros.24074","article-title":"Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805)","volume":"80","author":"Harshman","year":"2020","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.cca.2024.117824_b0665","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.21873\/anticanres.15090","article-title":"Are proinflammatory cytokines relevant for the diagnosis of prostate cancer?","volume":"41","author":"Garrido","year":"2021","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cca.2024.117824_b0670","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.3389\/fonc.2022.837127","article-title":"A novel combination of serum markers in a multivariate model to help triage patients into \u201clow-\u201d and \u201chigh-risk\u201d categories for prostate cancer","volume":"12","author":"McNally","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0675","doi-asserted-by":"crossref","first-page":"27","DOI":"10.21873\/anticanres.13923","article-title":"Genetic polymorphisms in IL-10 promoter are associated with smoking and prostate cancer risk in African Americans","volume":"40","author":"Abbas","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cca.2024.117824_b0680","first-page":"1","article-title":"Immunological analysis of Interleukin-10 (IL-10), tumor necrosis factor-a (TNF-a), and Prostate-specific antigen (PSA) in benign and malignant prostate cancer","author":"Al-Nasralla","year":"2023","journal-title":"Hum. Antibodies"},{"issue":"4","key":"10.1016\/j.cca.2024.117824_b0685","doi-asserted-by":"crossref","DOI":"10.4274\/imj.galenos.2021.70487","article-title":"Prognostic Role of interleukin-23 in prostate adenocarcinoma: comparison with gallium-68 prostate-specific membrane antigen-11 positron emission tomography\/computed tomography findings","volume":"22","author":"G\u00fcndo\u011fan","year":"2021","journal-title":"Istanbul Med. J."},{"key":"10.1016\/j.cca.2024.117824_b0690","first-page":"1","article-title":"IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model","volume":"18","author":"Wang","year":"2020","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.cca.2024.117824_b0695","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4103\/aja202173","article-title":"High IL-23+ cells infiltration correlates with worse clinical outcomes and abiraterone effectiveness in patients with prostate cancer","volume":"24","author":"Liu","year":"2022","journal-title":"Asian J. Androl."},{"issue":"2","key":"10.1016\/j.cca.2024.117824_b0700","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4103\/aja2021100","article-title":"Impact of IL-23 in prostate cancer","volume":"24","author":"Mirlekar","year":"2022","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.cca.2024.117824_b0705","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.692142","article-title":"Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis","volume":"11","author":"Kartikasari","year":"2021","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.cca.2024.117824_b0710","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/s41419-021-03909-z","article-title":"Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer","volume":"12","author":"Signore","year":"2021","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.cca.2024.117824_b0715","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/ijc.33873","article-title":"The effects of TNF-\u03b1\/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer","volume":"150","author":"Qu","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.cca.2024.117824_b0720","first-page":"292","article-title":"Do quercetin and vitamin e properties preclude doxorubicin-induced stress and inflammation in reproductive tissues?","volume":"18","author":"Samare-Najaf","year":"2022","journal-title":"Curr. Can. Therapy Rev."},{"issue":"2","key":"10.1016\/j.cca.2024.117824_b0725","first-page":"2939","article-title":"A Predictive clinical markers to make prostate cancer and benign prostate hyperplasia easy diagnosis","volume":"21","author":"Al-Fartosy","year":"2021","journal-title":"Biochem. Cell. Arch."},{"key":"10.1016\/j.cca.2024.117824_b0730","article-title":"Importance of TNF-alpha and its alterations in the development of cancers","volume":"130","author":"Sharif","year":"2020","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0735","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/HAB-190397","article-title":"Association between tumor necrosis factor-alpha gene rs1800629 (-308G\/A) and rs361525 (-238G> A) polymorphisms and prostate cancer risk in an Iranian cohort","volume":"28","author":"Alidoost","year":"2020","journal-title":"Hum. Antibodies"},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0740","doi-asserted-by":"crossref","first-page":"5","DOI":"10.24126\/jobrc.2020.14.1.582","article-title":"Tumor necrosis factor alpha as a potential marker for prostate cancer","volume":"14","author":"Ali","year":"2020","journal-title":"J. Biotechnol. Res. Center"},{"key":"10.1016\/j.cca.2024.117824_b0745","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomarker Res."},{"issue":"6","key":"10.1016\/j.cca.2024.117824_b0750","first-page":"14186","article-title":"The relationship of insulin resistance with some proinflammtory markers in prostate cancer and benign prostate hyperplasia patients","volume":"25","author":"AlFartosy","year":"2021","journal-title":"Ann. Romanian Soc. Cell Biol."},{"key":"10.1016\/j.cca.2024.117824_b0755","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3389\/fonc.2020.00493","article-title":"Quantitative SWATH-based proteomic profiling for identification of mechanism-driven diagnostic biomarkers conferring in the progression of metastatic prostate cancer","volume":"10","author":"Singh","year":"2020","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.cca.2024.117824_b0760","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/13685538.2019.1597840","article-title":"TGF-\u03b2\/PI3K\/AKT\/mTOR\/NF-kB pathway. Clinicopathological features in prostate cancer","volume":"23","author":"Torrealba","year":"2020","journal-title":"Aging Male"},{"key":"10.1016\/j.cca.2024.117824_b0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.110240","article-title":"Activation of TGF-\u03b2-SMAD2 signaling by IL-6 drives neuroendocrine differentiation of prostate cancer through p38MAPK","volume":"91","author":"Natani","year":"2022","journal-title":"Cell. Signal."},{"key":"10.1016\/j.cca.2024.117824_b0770","unstructured":"N. Lou, Y. Shi, X. Han, Tumor autoantibodies in the diagnosis and prognosis of prostate cancer. Chinese J. Laborat. Med., 2021: p. 260-264."},{"issue":"2","key":"10.1016\/j.cca.2024.117824_b0775","article-title":"Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages","volume":"8","author":"Potluri","year":"2020","journal-title":"J. ImmunoTherapy Can."},{"issue":"2","key":"10.1016\/j.cca.2024.117824_b0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2021.152174","article-title":"Monitoring of autoantibodies against CYP4Z1 in patients with colon, ovarian, or prostate cancer","volume":"227","author":"Khayeka-Wandabwa","year":"2022","journal-title":"Immunobiology"},{"issue":"23","key":"10.1016\/j.cca.2024.117824_b0785","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1158\/1078-0432.CCR-20-1966","article-title":"Autoantibody landscape in patients with advanced prostate cancerautoantibody landscape of advanced prostate cancer","volume":"26","author":"Chen","year":"2020","journal-title":"Clin. Can. Res."},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0790","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00262-022-03242-0","article-title":"Identification of novel serological autoantibodies in Chinese prostate cancer patients using high-throughput protein arrays","volume":"72","author":"Lou","year":"2023","journal-title":"Can. Immunol. Immunother."},{"key":"10.1016\/j.cca.2024.117824_b0795","doi-asserted-by":"crossref","unstructured":"Nanami, T., et al., Presence of serum RalA and serum p53 autoantibodies in 1833 patients with various types of cancers. Int. J. Clin. Oncol. 2022: p. 1-5.","DOI":"10.1007\/s10147-021-02045-0"},{"key":"10.1016\/j.cca.2024.117824_b0800","doi-asserted-by":"crossref","first-page":"8345","DOI":"10.12659\/MSM.916900","article-title":"Significant diagnostic value of free-serum PSA (FPSA)\/Prostate-specific antigen density (PSAD) and (F\/T)\/PSAD for prostate cancer of the Chinese population in a single institution","volume":"25","author":"Nan","year":"2019","journal-title":"Med. Sci. Monit.: Int. Med. J. Exp. Clin. Res."},{"issue":"3","key":"10.1016\/j.cca.2024.117824_b0805","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0090-4295(98)00208-8","article-title":"Determination of the site of metabolism of total, free, and complexed prostate-specific antigen","volume":"52","author":"Kilic","year":"1998","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.cca.2024.117824_b0810","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1515\/cclm-2019-0693","article-title":"Biomarkers for prostate cancer: prostate-specific antigen and beyond","volume":"58","author":"Duffy","year":"2020","journal-title":"Clin. Chem. Laborat. Med. (CCLM)"},{"issue":"3","key":"10.1016\/j.cca.2024.117824_b0815","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CCO.0000000000000065","article-title":"Biomarkers in prostate cancer: what\u2019s new?","volume":"26","author":"Sartori","year":"2014","journal-title":"Curr. Opin. Oncol."},{"issue":"4","key":"10.1016\/j.cca.2024.117824_b0820","first-page":"343","article-title":"Clinical performance of serum [-2] proPSA derivatives,% p2PSA and PHI, in the detection and management of prostate cancer","volume":"2","author":"Huang","year":"2014","journal-title":"Am. J. Clin. Exp. Urol."},{"issue":"3","key":"10.1016\/j.cca.2024.117824_b0825","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bju.12217","volume":"112","author":"Lazzeri","year":"2013","journal-title":"BJU Int."},{"issue":"9","key":"10.1016\/j.cca.2024.117824_b0830","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/1878-0261.12348","article-title":"Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer","volume":"12","author":"Murphy","year":"2018","journal-title":"Mol. Oncol."},{"issue":"3","key":"10.1016\/j.cca.2024.117824_b0835","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.urology.2013.10.016","article-title":"Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2] proPSA (p2PSA),% p2PSA, and prostate health index in men with a total prostate-specific antigen of 4\u201310 ng\/ml and normal digital rectal examination","volume":"83","author":"Lazzeri","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.cca.2024.117824_b0840","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.cca.2022.04.992","article-title":"Value of PHI and PHID in the detection of intermediate-and high-risk prostate cancer","volume":"531","author":"Filella","year":"2022","journal-title":"Clin. Chim. Acta"},{"issue":"8","key":"10.1016\/j.cca.2024.117824_b0845","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1515\/cclm-2022-0354","article-title":"Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis","volume":"60","author":"Agnello","year":"2022","journal-title":"Clin. Chem. Laborat. Med. (CCLM)"},{"key":"10.1016\/j.cca.2024.117824_b0850","unstructured":"Urology, E.A.o. EAU guidelines: prostate cancer: Uroweb; 2022. 2022; Available from: https:\/\/uroweb.org\/guidelines\/prostate-cancer#5."},{"key":"10.1016\/j.cca.2024.117824_b0855","unstructured":"Association., A.U. Prostate cancer: early detection guideline \u2013 American urological association; 2013. Available from: https:\/\/www.auanet.org\/guidelines\/prostate-cancer-early-detection-guideline."},{"key":"10.1016\/j.cca.2024.117824_b0860","article-title":"Modified prostate health index density significantly improves clinically significant prostate cancer (csPCa) detection","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2024.117824_b0865","article-title":"Galectin-3 as a new negative checkpoint of the immune response is the key target for effective immunotherapy against prostate cancer","author":"Tiraboschi","year":"2019","journal-title":"BioRxiv"},{"issue":"2","key":"10.1016\/j.cca.2024.117824_b0870","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000356240","article-title":"Evaluation of prostate-specific antigen isoform p2PSA and its derivates,% p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study","volume":"93","author":"Mearini","year":"2014","journal-title":"Urol. Int."},{"issue":"6","key":"10.1016\/j.cca.2024.117824_b0875","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/bju.13762","article-title":"Prostate Health Index density improves detection of clinically significant prostate cancer","volume":"120","author":"Tosoian","year":"2017","journal-title":"BJU Int."},{"key":"10.1016\/j.cca.2024.117824_b0880","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.urology.2017.08.019","article-title":"Prostate-specific antigen parameters and prostate health index enhance prostate cancer prediction with the in-bore 3-T magnetic resonance imaging-guided transrectal targeted prostate biopsy after negative 12-core biopsy","volume":"110","author":"Friedl","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.cca.2024.117824_b0885","first-page":"1","article-title":"PHI density prospectively improves prostate cancer detection","author":"Stephan","year":"2021","journal-title":"World J. Urol."},{"issue":"9","key":"10.1016\/j.cca.2024.117824_b0890","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1159\/000517891","article-title":"Comparison of PHI and PHI density for prostate cancer detection in a large retrospective Caucasian cohort","volume":"106","author":"Peters","year":"2022","journal-title":"Urol. Int."},{"issue":"4","key":"10.1016\/j.cca.2024.117824_b0895","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s11255-022-03113-8","article-title":"The modified prostate health index (PHI) outperforms PHI density in the detection of clinical prostate cancer within the PSA grey zone","volume":"54","author":"Chen","year":"2022","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.cca.2024.117824_b0900","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.urology.2020.02.032","article-title":"Concordance and performance of 4Kscore and SelectMDx for informing decision to perform prostate biopsy and detection of prostate cancer","volume":"141","author":"Wysock","year":"2020","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.cca.2024.117824_b0905","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/1055-9965.EPI-10-1003","article-title":"A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening","volume":"20","author":"Vickers","year":"2011","journal-title":"Can. Epidemiol. Biomark. Prev."},{"issue":"5","key":"10.1016\/j.cca.2024.117824_b0910","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2013.04.040","article-title":"Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam","volume":"64","author":"Carlsson","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.cca.2024.117824_b0915","doi-asserted-by":"crossref","unstructured":"C. Mi, et al. 4Kscore diagnostic value in patients with high-grade prostate cancer using cutoff values of 7.5% to 10%: A meta-analysis. in Urologic Oncology: Seminars and Original Investigations. 2021. Elsevier.","DOI":"10.1016\/j.urolonc.2020.11.001"},{"key":"10.1016\/j.cca.2024.117824_b0920","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2023.03.011","article-title":"Implementation of 4Kscore as a secondary test before prostate biopsy: impact on us population trends for prostate cancer","volume":"52","author":"Scuderi","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"issue":"2","key":"10.1016\/j.cca.2024.117824_b0925","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/JU.0000000000001361","article-title":"Clinical utility of 4Kscore\u00ae, ExosomeDx\u2122 and magnetic resonance imaging for the early detection of high grade prostate cancer","volume":"205","author":"de la Calle","year":"2021","journal-title":"J. Urol."},{"key":"10.1016\/j.cca.2024.117824_b0930","series-title":"Urologic Oncology: Seminars and Original Investigations","article-title":"Developing an effective strategy to improve the detection of significant prostate cancer by combining the 4Kscore and multiparametric MRI","author":"Marzouk","year":"2019"},{"issue":"4","key":"10.1016\/j.cca.2024.117824_b0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2016.12.022","article-title":"A systematic review and meta-analysis of the diagnostic accuracy of prostate health index and 4-kallikrein panel score in predicting overall and high-grade prostate cancer","volume":"15","author":"Russo","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"issue":"3","key":"10.1016\/j.cca.2024.117824_b0940","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0090-4295(97)00177-5","article-title":"Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase","volume":"49","author":"Heston","year":"1997","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.cca.2024.117824_b0945","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.euf.2021.06.006","article-title":"Prostate-specific membrane antigen biology in lethal prostate cancer and its therapeutic implications","volume":"8","author":"Sheehan","year":"2022","journal-title":"Eur. Urol. Focus"},{"issue":"11","key":"10.1016\/j.cca.2024.117824_b0950","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3390\/cancers14112704","article-title":"Use of glycoproteins\u2014prostate-specific membrane antigen and galectin-3 as primary tumor markers and therapeutic targets in the management of metastatic prostate cancer","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.cca.2024.117824_b0955","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/molbev\/msh082","article-title":"Phylogenetic analysis of the vertebrate galectin family","volume":"21","author":"Houzelstein","year":"2004","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.cca.2024.117824_b0960","doi-asserted-by":"crossref","first-page":"1124111","DOI":"10.3389\/fendo.2023.1124111","article-title":"Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor","volume":"14","author":"Souza","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.cca.2024.117824_b0965","first-page":"1323","article-title":"Improving the detection of aggressive prostate cancer using immunohistochemical staining of protein marker panels","volume":"12","author":"Li","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.cca.2024.117824_b0970","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/pros.20688","article-title":"Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer","volume":"68","author":"Merseburger","year":"2008","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.cca.2024.117824_b0975","doi-asserted-by":"crossref","first-page":"542","DOI":"10.18632\/oncotarget.923","article-title":"Galectin-3: a possible complementary marker to the PSA blood test","volume":"4","author":"Balan","year":"2013","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.cca.2024.117824_b0980","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/1097-0215(20000720)89:4<361::AID-IJC8>3.0.CO;2-U","article-title":"Alteration of the cytoplasmic\/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression","volume":"89","author":"van den Br\u00fble","year":"2000","journal-title":"Int. J. Cancer"},{"issue":"45","key":"10.1016\/j.cca.2024.117824_b0985","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.1038\/sj.onc.1207997","article-title":"Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3","volume":"23","author":"Califice","year":"2004","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.cca.2024.117824_b0990","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/clinchem\/24.3.466","article-title":"Purification of human prostatic acid phosphatase by affinity chromatography and isoelectric focusing. Part I","volume":"24","author":"Vihko","year":"1978","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.cca.2024.117824_b0995","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1006\/geno.1993.1403","article-title":"The prostatic acid phosphatase (ACPP) gene is localized to human chromosome 3q21-q23","volume":"17","author":"Li","year":"1993","journal-title":"Genomics"},{"issue":"26","key":"10.1016\/j.cca.2024.117824_b1000","doi-asserted-by":"crossref","first-page":"11892","DOI":"10.7150\/thno.47066","article-title":"Urinary glycoproteins associated with aggressive prostate cancer","volume":"10","author":"Dong","year":"2020","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.cca.2024.117824_b1005","doi-asserted-by":"crossref","first-page":"9172","DOI":"10.1021\/acsomega.1c05223","article-title":"Comparing urinary glycoproteins among three urogenital cancers and identifying prostate cancer-specific glycoproteins","volume":"7","author":"Chen","year":"2022","journal-title":"ACS Omega"},{"issue":"6","key":"10.1016\/j.cca.2024.117824_b1010","doi-asserted-by":"crossref","first-page":"e14067","DOI":"10.1111\/and.14067","article-title":"Screening of differentially expressed genes and identification of AMACR as a prognostic marker in prostate cancer","volume":"53","author":"Fu","year":"2021","journal-title":"Andrologia"},{"issue":"10","key":"10.1016\/j.cca.2024.117824_b1015","doi-asserted-by":"crossref","first-page":"e74386","DOI":"10.1371\/journal.pone.0074386","article-title":"A-methylacyl-CoA racemase (AMACR) and prostate-cancer risk: a meta-analysis of 4,385 participants","volume":"8","author":"Jiang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2024.117824_b1020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.904315","article-title":"Urine Exosomal AMACR is a novel biomarker for prostate cancer detection at initial biopsy","volume":"12","author":"Jin","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2024.117824_b1025","first-page":"403","article-title":"Identification of clinically significant prostate cancer by combined PCA3 and AMACR mRNA detection in urine samples","author":"Kotova","year":"2020","journal-title":"Res. Rep. Urol."},{"issue":"10","key":"10.1016\/j.cca.2024.117824_b1030","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1593\/neo.06625","article-title":"Noninvasive detection of TMPRSS2: ERG fusion transcripts in the urine of men with prostate cancer","volume":"8","author":"Laxman","year":"2006","journal-title":"Neoplasia"},{"issue":"17","key":"10.1016\/j.cca.2024.117824_b1035","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1158\/1078-0432.CCR-07-0700","article-title":"Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer","volume":"13","author":"Hessels","year":"2007","journal-title":"Clin. Can. Res."},{"key":"10.1016\/j.cca.2024.117824_b1040","doi-asserted-by":"crossref","unstructured":"S.A. Tomlins, et al., Urine TMPRSS2: ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Translat. Med., 2011. 3(94): p. 94ra72-94ra72.","DOI":"10.1126\/scitranslmed.3001970"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124000652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124000652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:06:10Z","timestamp":1762113970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898124000652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":207,"alternative-id":["S0009898124000652"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2024.117824","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate cancer: Novel genetic and immunologic biomarkers","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2024.117824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117824"}}